Back to top
more

Adherex Technologies (FENC)

(Real Time Quote from BATS)

$9.18 USD

9.18
13,107

-0.03 (-0.33%)

Updated Apr 29, 2024 12:46 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (91 out of 252)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Adherex Technologies Inc. (FENC) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Adherex Technologies (FENC) delivered earnings and revenue surprises of -600% and 2.80%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Fennec (FENC) Signs Licensing Deal With Norgine, Stock Up

by Zacks Equity Research

Fennec (FENC) signs a licensing deal with Nordine, granting the latter rights to Pedmarqsi in the EU, Australia and New Zealand to treat cisplatin-induced hearing loss. The stock rises 11.4%.

Adherex Technologies Inc. (FENC) is on the Move, Here's Why the Trend Could be Sustainable

by Zacks Equity Research

Adherex Technologies Inc. (FENC) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

Wall Street Analysts See a 64.61% Upside in Adherex Technologies Inc. (FENC): Can the Stock Really Move This High?

by Zacks Equity Research

The consensus price target hints at a 64.6% upside potential for Adherex Technologies Inc. (FENC). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Recent Price Trend in Adherex Technologies Inc. (FENC) is Your Friend, Here's Why

by Zacks Equity Research

Adherex Technologies Inc. (FENC) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.

Wall Street Analysts Think Adherex Technologies Inc. (FENC) Could Surge 81%: Read This Before Placing a Bet

by Zacks Equity Research

The mean of analysts' price targets for Adherex Technologies Inc. (FENC) points to an 81% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts Believe Adherex Technologies Inc. (FENC) Could Rally 109.97%: Here's is How to Trade

by Zacks Equity Research

The consensus price target hints at a 110% upside potential for Adherex Technologies Inc. (FENC). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Adherex Technologies Inc. (FENC) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Adherex Technologies Inc. (FENC) delivered earnings and revenue surprises of 36.36% and 24.90%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Adherex Technologies Inc. (FENC) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Adherex Technologies Inc. (FENC) delivered earnings and revenue surprises of -16.67% and 17.12%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Adherex Technologies Inc. (FENC) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Adherex Technologies Inc. (FENC) delivered earnings and revenue surprises of -9.52% and 10.61%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Adherex Technologies Inc. (FENC) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

Adherex Technologies Inc. (FENC) delivered earnings and revenue surprises of -8.33% and 100%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Why Earnings Season Could Be Great for Adherex Technologies (FENC)

by Zacks Equity Research

Adherex Technologies (FENC) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Feneca (FENC) Gets FDA Nod for Cancer-Related Hearing Loss Drug

by Zacks Equity Research

Feneca Pharmaceuticals (FENC) receives FDA approval for Pedmark to reduce the risk of ototoxicity associated with cisplatin in pediatric patients with localized, non-metastatic solid tumors.

Has Bellus Health (BLU) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Bellus Health (BLU) and Adherex Technologies Inc. (FENC) have performed compared to their sector so far this year.

Has Adherex Technologies (FENC) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Adherex Technologies Inc. (FENC) and U.S. Physical Therapy (USPH) have performed compared to their sector so far this year.

Are Medical Stocks Lagging Bellus Health (BLU) This Year?

by Zacks Equity Research

Here is how Bellus Health (BLU) and Adherex Technologies Inc. (FENC) have performed compared to their sector so far this year.

Wall Street Analysts Predict an 80% Upside in Adherex Technologies Inc. (FENC): Here's What You Should Know

by Zacks Equity Research

The mean of analysts' price targets for Adherex Technologies Inc. (FENC) points to an 80.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Is Bellus Health (BLU) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Bellus Health (BLU) and Adherex Technologies Inc. (FENC) have performed compared to their sector so far this year.

Can Adherex Technologies Inc. (FENC) Climb 92% to Reach the Level Wall Street Analysts Expect?

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 91.9% in Adherex Technologies Inc. (FENC). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Has Anixa Biosciences (ANIX) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Here is how ANIXA BIOSCIENCES INC (ANIX) and Adherex Technologies Inc. (FENC) have performed compared to their sector so far this year.

New Strong Sell Stocks for April 5th

by Zacks Equity Research

FENC, ALKT, and AMADY have been added to the Zacks Rank #5 (Strong Sell) List on April 5, 2022.

Fennec (FENC) Gets CRL From FDA for Pedmark, Stock Down

by Zacks Equity Research

Fennec (FENC) suffers a setback again with a CRL for its new drug application (NDA) for Pedmark. Shares are down in pre-market trading.

Adherex Technologies Inc. (FENC) is on the Move, Here's Why the Trend Could be Sustainable

by Zacks Equity Research

Adherex Technologies Inc. (FENC) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.

Nitish Marwah headshot

4 Breakout Stocks for Impressive Returns

by Nitish Marwah

SB, VTSI, FENC and APYX qualified the screen for breakout stocks for today.

Here's Why "Trend" Investors Would Love Betting on Adherex Technologies Inc. (FENC)

by Zacks Equity Research

Adherex Technologies Inc. (FENC) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.